Zemcelpro® receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

ExCellThera Quebec

If approved, Zemcelpro® is expected to:increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromesbe the first and only therapy in the European Union with marketing authorization for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is availableApproval decision from the European Commission expected within approximately two monthsView original content:https://www.prnewswire.co.uk/news-releases/zemcelpro-um171-cell-therapy-receives-positive-chmp-opinion-for-treatment-of-blood-cancer-patients-without-access-to-suitable-donor-cells-302486395.html